Hiberix (Haemophilus Type B Conjugate Vaccine (Tetanus Toxoid Conjugate))

Hiberix is indicated for the prevention of disease caused by Haemophilus influenzae type b (Hib).

• Primary immunization of infants according to national vaccination schedules.
• Booster doses in children who have completed the primary series.
• Immunization of adolescents who have not previously received Hib vaccine.
• Use in travelers to regions where Hib disease remains endemic.
• Administration to individuals with certain immunodeficiency conditions when recommended by a healthcare professional.

• The vaccine contains Hib capsular polysaccharide (polyribosyl‑ribitol‑phosphate) covalently linked to tetanus toxoid protein. After intramuscular or subcutaneous injection, antigen‑presenting cells process the conjugate and present peptide fragments to helper T cells. This T‑cell help drives B‑cell activation and class‑switching, resulting in the production of high‑affinity anti‑PRP IgG antibodies that neutralize the bacterium and prevent invasive disease. The immune memory generated provides long‑term protection.

Local and systemic reactions may occur after injection of Hiberix, most of which are mild and self‑limiting.

Common

• Pain, redness, or swelling at the injection site.
• Low‑grade fever (up to 38 °C) within 24 hours.
• Irritability or fussiness in infants.
• Decreased appetite or mild malaise.
• Headache or mild malaise.

Serious

• Anaphylactic or severe allergic reaction.
• High fever (≥40 °C) or febrile seizures.
• Seizures not associated with fever.
• Hypotension or shock.
• Rare neurologic events such as Guillain‑Barré syndrome.

Healthcare providers should assess each patient’s medical history before administering Hiberix to minimize the risk of adverse events.

• Do not give to individuals with a known severe allergy to any vaccine component.
• Postpone vaccination in persons with moderate or severe acute illness.
• Observe the patient for at least 15 minutes after injection for immediate reactions.
• Use caution in patients with a history of seizures or neurologic disorders.
• Consider deferring vaccination in immunocompromised patients unless benefits outweigh risks.
• Document any prior Hib vaccination to avoid unnecessary repeat dosing.

Hiberix does not have many documented drug‑drug interactions, but certain concomitant therapies may influence its safety profile.

Avoid

• Administration of other live bacterial vaccines (e.g., oral typhoid) within 4 weeks before or after Hiberix.

Use with caution

• Concurrent use of immunosuppressive agents may reduce antibody response.
• Antipyretics (acetaminophen, ibuprofen) may mask fever after vaccination.
• Blood products or immunoglobulins given within 3 months may interfere with vaccine efficacy.
• Severe allergic reactions to previous vaccines may warrant extended observation.